bispecific antibodies
| 3 min read
The newly approved drug vastly reduced the amount of antibodies that would usually lead to organ rejection in a patient who had no chance of receiving a matched transplant.
| 3 min read
An integrated workflow brings charge and size analysis together for faster, more informative bispecific antibody characterization.
| 2 min read
The integrated workflow combines icIEF fractionation and mass photometry, enabling simultaneous assessment of charge and size variants at single molecule resolution .
| 2 min read
The updated brand identity underscores nearly 30 years of scientific leadership and a growing portfolio designed for modern preclinical discovery.
| 4 min read
Cancer researchers in biotech and pharma highlight the clinical trials and developments they’re most excited about.
| 1 min read
ProBioGen announced the commercial launch of Ziihera®, a bispecific antibody for HER2-positive biliary tract cancer developed with its GlymaxX® technology.
Available on Demand
Antibodies that simultaneously target two distinct antigens overcome cancer therapy resistance by addressing antigenic diversity and diminished T cell action.
Page 1 of 1 - 7 Total Items
